These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 1261151)

  • 1. Phenytoin: pharmacokinetics and bioavailability.
    Gugler R; Manion CV; Azarnoff DL
    Clin Pharmacol Ther; 1976 Feb; 19(2):135-42. PubMed ID: 1261151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single dose comparison of the relative bioavailability of phenytoin suspension and extended capsules.
    Fitzsimmons WE; Garnett WR; Comstock TJ; Pellock JM
    Epilepsia; 1986; 27(4):464-8. PubMed ID: 3720707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioavailability of ACC-9653 (phenytoin prodrug).
    Browne TR; Davoudi H; Donn KH; Dougherty CL; Dukes GE; Evans B; Evans JE; Jamerson B; Kres J; McEntegart CM
    Epilepsia; 1989; 30 Suppl 2():S27-32. PubMed ID: 2670536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative study of the bioavailability of five different phenytoin preparations.
    Hirji MR; Measuria H; Kuhn S; Mucklow JC
    J Pharm Pharmacol; 1985 Aug; 37(8):570-2. PubMed ID: 2864420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenytoin prodrugs V: In vivo evaluation of some water-soluble phenytoin prodrugs in dogs.
    Varia SA; Stella VJ
    J Pharm Sci; 1984 Aug; 73(8):1080-7. PubMed ID: 6548519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of dose on phenytoin absorption.
    Jung D; Powell JR; Walson P; Perrier D
    Clin Pharmacol Ther; 1980 Oct; 28(4):479-85. PubMed ID: 7408408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of doses on the bioavailability of phenytoin from a prompt-release and an extended-release preparation: single dose study.
    Rojanasthien N; Chaichana N; Teekachunhatean S; Kumsorn B; Sangdee C; Chankrachang S
    J Med Assoc Thai; 2007 Sep; 90(9):1883-93. PubMed ID: 17957935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacokinetics of phenytoin in the dog: a reevaluation.
    Frey HH; Löscher W
    Am J Vet Res; 1980 Oct; 41(10):1635-8. PubMed ID: 6784613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disposition, elimination, and bioavailability of phenytoin and its major metabolite in horses.
    Soma LR; Uboh CE; Guan F; Birks EK; Teleis DC; Rudy JA; Tsang DS; Watson AO
    Am J Vet Res; 2001 Apr; 62(4):483-9. PubMed ID: 11327452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioavailability and single-dose pharmacokinetics of intramuscular phenytoin.
    Kostenbauder HB; Rapp RP; McGovren JP; Foster TS; Perrier DG; Blacker HM; Hulon WC; Kinkel AW
    Clin Pharmacol Ther; 1975 Oct; 18(4):449-56. PubMed ID: 1100308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers.
    Taylor TJ; Diringer K; Russell T; Venkatakrishnan K; Wilner K; Crownover PH; Benincosa LJ; Gibbs MA
    Clin Pharmacokinet; 2006; 45(10):989-1001. PubMed ID: 16984212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of phenytoin (diphenylhydantoin) in horses.
    Kowalczyk DF; Beech J
    J Vet Pharmacol Ther; 1983 Jun; 6(2):133-40. PubMed ID: 6887340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison between microcrystalline and conventional phenytoin preparations: relative bioavailability and steady-state plasma concentrations.
    Boréus LO; Nergårdh A; Ehrnebo M; Theorell K
    J Neurol; 1980; 223(4):241-9. PubMed ID: 6157786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic interaction between intravenous phenytoin and amiodarone in healthy volunteers.
    Nolan PE; Marcus FI; Hoyer GL; Bliss M; Gear K
    Clin Pharmacol Ther; 1989 Jul; 46(1):43-50. PubMed ID: 2743707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative bioavailability of 2 oral solid phenytoin dosage forms.
    Naik D; Morton DJ
    Cent Afr J Med; 1989 Apr; 35(4):384-8. PubMed ID: 2605620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stable-isotope methodology for the bioavailability study of phenytoin during multiple-dosing regimens.
    Kasuya Y; Mamada K; Baba S; Matsukura M
    J Pharm Sci; 1985 May; 74(5):503-7. PubMed ID: 4020625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of indomethacin.
    Alván G; Orme M; Bertilsson L; Ekstrand R; Palmér L
    Clin Pharmacol Ther; 1975 Sep; 18(3):364-73. PubMed ID: 1100305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Steady-state plasma concentrations as a function of the absorption rate and dosing interval for drugs exhibiting concentration-dependent clearance: consequences for phenytoin therapy.
    Sawchuk RJ; Rector TS
    J Pharmacokinet Biopharm; 1979 Dec; 7(6):543-55. PubMed ID: 529023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenytoin prodrug 3-phosphoryloxymethyl phenytoin (ACC-9653): pharmacokinetics in patients following intravenous and intramuscular administration.
    Boucher BA; Bombassaro AM; Rasmussen SN; Watridge CB; Achari R; Turlapaty P
    J Pharm Sci; 1989 Nov; 78(11):929-32. PubMed ID: 2621577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioavailability and pharmacokinetics of phenytoin during pregnancy.
    Lander CM; Smith MT; Chalk JB; de Wytt C; Symoniw P; Livingstone I; Eadie MJ
    Eur J Clin Pharmacol; 1984; 27(1):105-10. PubMed ID: 6489420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.